D. Toumpanakis (Athens, Greece), B. Kane (Warringtom, United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
CAPTAIN: Improvements in airflow obstruction in patients with uncontrolled asthma
D. Singh (Manchester, United Kingdom), Z. Bailes (Brentford, Middlesex, United Kingdom), N. Barnes (Brentford, Middlesex & London, United Kingdom), L. Boulet (Quebec, Canada), R. Buhl (Mainz, Germany), R. Chaudhuri (Glasgow, United Kingdom), F. Gardiner (Brentford, Middlesex, United Kingdom), I. Pavord (Oxford, United Kingdom), E. Pizzichini (Brentford, Middlesex & Santa Catarina, United Kingdom), D. Slade (Research Triangle Park, NC, United States of America), C. Vogelmeier (Marburg, Germany), J. Oppenheimer (Newark, NJ, United States of America)
|   |
CAPTAIN: Relationship between FEV1 reversibility at screening as a continuous variable and treatment response
G. Brusselle (Ghent, Belgium), N. Barnes (Brentford, Middlesex & London, United Kingdom), R. Buhl (Mainz, Germany), F. Gardiner (Brentford, Middlesex, United Kingdom), L. Heaney (Belfast, United Kingdom), H. Inoue (Kagoshima, Japan), G. Mosnaim (Evanston, IL, United States of America), A. Papi (Ferrara, Italy), E. Pizzichini (Brentford, Middlesex & Santa Catarina, United Kingdom), J. Tamaoki (Tokyo, Japan), C. Vogelmeier (Marburg, Germany), A. Zarankaite (Brentford, Middlesex, United Kingdom), I. Pavord (Oxford, United Kingdom)
| |
Mometasone/indacaterol (MF/IND) and mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) and FLU/SAL+tiotropium (TIO) in patients with inadequately controlled asthma: data from the PLATINUM program
R. Van Zyl-Smit (Cape Town, South Africa), K. Chapman (Toronto, Canada), H. Kerstjens (Groningen, Netherlands), C. Gessner (Leipzig, Germany), H. Sagara (Tokyo, Japan), A. Tanase (Basel, Switzerland), M. Hosoe (Basel, Switzerland), X. Shu (East Hanover, United States of America), A. Pethe (East Hanover, United States of America), D. Lawrence (Basel, Switzerland), H. Tillmann (Basel, Switzerland), K. Mezzi (Basel, Switzerland), P. D’Andrea (East Hanover, United States of America)
| |
CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA
H. Kerstjens (Groningen, Netherlands), C. Abbott (Research Triangle Park, NC, United States of America), L. Boulet (Quebec, Canada), S. Chang (Research Triangle Park, NC, United States of America), G. Chupp (New Haven, CT, United States of America), J. Crawford (Brentford, Middlesex, United Kingdom), N. Hanania (Houston, TX, United States of America), R. Nathan (Colorado Springs, CO, United States of America), J. Oppenheimer (Newark, NJ, United States of America), E. Pizzichini (Brentford, Middlesex & Santa Catarina, United Kingdom), H. Sagara (Tokyo, Japan), W. Busse (Madison, WI, United States of America)
| |
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study
H. Kerstjens (Groningen, Netherlands), R. Van Zyl-Smit (Cape Town, South Africa), K. Chapman (Toronto, Canada), J. Maspero (Buenos Aires, Argentina), M. Hosoe (Basel, Switzerland), A. Tanase (Basel, Switzerland), D. Lawrence (Basel, Switzerland), A. Pethe (NJ, United States of America), X. Shu (NJ, United States of America), K. Mezzi (Basel, Switzerland), P. D'Andrea (NJ, United States of America)
| |
Mometasone/indacaterol demonstrates similar efficacy in men and women: pooled analyses of PALLADIUM and IRIDIUM studies
C. Gessner (Leipzig, Germany), R. Van Zyl-Smit (Cape Town, South Africa), D. Singh (Manchester, United Kingdom), H. A.M. Kerstjens (Groningen, Netherlands), C. Raherison-Semjen (Bordeaux, France), D. Lawrence (Basel, Switzerland), A. Pethe (New Jersey, United States of America), A. Tanase (Basel, Switzerland), K. Mezzi (Basel, Switzerland), P. D'Andrea (New Jersey, United States of America)
| |
Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study
C. Raherison-Semjen (Pessac, Bordeaux, France), D. Singh (Manchester, United Kingdom), H. A.M Kerstjens (Groningen, Netherlands), C. Gessner (Leipzig, Germany), A. Tanase (Basel, Switzerland), D. Lawrence (Basel, Switzerland), A. Pethe (New Jersey, United States of America), K. Mezzi (Basel, Switzerland), P. D'Andrea (New Jersey, United States of America)
| |
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study
H. Kerstjens (Groningen, Netherlands), J. F Maspero (Buenos Aires, Argentina), K. R Chapman (Toronto, Canada), R. Van Zyl-Smit (Cape Town, South Africa), A. Tanase (Basel, Switzerland), D. Lawrence (East Hanover, United States of America), A. Pethe (East Hanover, United States of America), K. Mezzi (Basel, Switzerland), P. D'Andrea (East Hanover, United States of America)
| |
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study
J. Maspero (Buenos Aires, Argentina), H. A M Kerstjens (Groningen, Netherlands), K. R Chapman (Toronto, Canada), R. Van Zyl-Smit (Cape Town, South Africa), A. Tanase (Basel, Switzerland), D. Lawrence (East Hanover, United States of America), A. Pethe (East Hanover, United States of America), K. Mezzi (Basel, Switzerland), P. D'Andrea (East Hanover, United States of America)
| |
Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study
K. Kostikas (Ioannina, Greece), H. A M Kerstjens (Groningen, Netherlands), J. F Maspero (Buenos Aires, Argentina), K. R Chapman (Toronto, Canada), R. N Van Zyl-Smit (Cape Town, South Africa), M. Hosoe (Basel, Switzerland), A. Tanase (Basel, Switzerland), A. Pethe (East Hanover, United States of America), I. Kottakis (Basel, Switzerland), P. D'Andrea (East Hanover, United States of America)
| |
Self-reported vs. objectively assessed adherence to inhaled corticosteroids in asthma
F. Jensen (Hvidovre, Denmark), K. Haakansson (Hvidovre, Denmark), B. Nielsen (Aaalborg, Denmark), U. Weinreich (Aaalborg, Denmark), C. Suppli Ulrik (Hvidovre, Denmark)
| |
Community pharmacist counseling improves adherence and asthma control: a nationwide observational study
B. Putman (Ghent, Belgium), A. Vanoverschelde (Ghent, Belgium), E. Mehuys (Ghent, Belgium), L. Coucke (Ghent, Belgium), L. Lahousse (Ghent, Belgium)
| |
Use of short-acting ß2-agonists in patients with adult-onset asthma during 12-years
I. Vähätalo (Seinäjoki and Tampere, Finland), H. Kankaanranta (Seinäjoki, Tampere and Gothenburg, Finland), L. Tuomisto (Seinäjoki and Tampere, Finland), O. Niemelä (Seinäjoki and Tampere, Finland), L. Lehtimäki (Tampere, Finland), P. Ilmarinen (Seinäjoki and Tampere, Finland)
| |
Lung deposition and distribution of inhaled extra fine beclomethasone dipropionate / formoterol fumarate /glycopyrronium bromide (BDP/FF/GB) in subjects with and without airflow obstruction.
S. Baldi (Parma, Italy), O. Usmani (London, United Kingdom), S. Warren (Cardiff, United Kingdom), I. Panni (Parma, Italy), L. Girardello (Verona, Italy), F. Rony (Parma, Italy), G. Taylor (Cardiff, United Kingdom), W. De Backer (Antwerp, Belgium), G. Georges (Parma, Italy)
| |
SABA use increase weeks before asthma exacerbations recorded via a digital inhaler
M. Levy (London, United Kingdom), G. Safioti (Amsterdam, Netherlands), M. Reich (Petah Tikva, Israel), R. Brown (West Chester, PA, United States of America), M. Depietro (West Chester, PA, United States of America)
| |
Real life data on the use of inhaler device, the satisfaction and the adherence of treatment evaluated by the pharmacists
B. Gemicioglu (Istanbul, Turkey), N. Mazican (Istanbul, Turkey), G. Can (Istanbul, Turkey), I. Alp Yildirim (Istanbul, Turkey), S. Uydes Dogan (Istanbul, Turkey)
| |
The sustainability agenda and inhaled therapy: what do patients want?
G. D'Ancona (London, United Kingdom), A. Cumella (London, United Kingdom), C. Renwick (London, United Kingdom), S. Walker (London, United Kingdom)
| |
Change from MDI to DPI in asthma: effects on climate emissions and disease control
A. Woodcock (Manchester , United Kingdom), J. Rees (Brentford, United Kingdom), D. Leather (Brentford, United Kingdom), L. Frith (Brentford, United Kingdom), M. Lofdahl (Solna, Sweden), A. Moore (Brentford, United Kingdom), M. Hedberg (Nacka, Sweden), C. Janson (Uppsala, Sweden)
| |
Efficiency of a Nebulizer Filter Kit to Prevent Environmental Contamination During Nebulizer Therapy
M. Nagel (London (ON), Canada), N. Hoffman (London (ON), Canada), J. Suggett (London (ON), Canada)
| |
Drug Delivery Performance and Fugitive Emission Comparison of Two Commercially Available Nebulizer Systems
M. Nagel (London (ON), Canada), N. Hoffman (London (ON), Canada), J. Suggett (London (ON), Canada)
| |